Last reviewed: May 12, 2026
Last updated: May 12, 2026
Written by:
Jay Hastings
,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub. Explore evidence-based guidance on GLP-1 therapies, weight management, and the genetics behind every metabolic decision. Browse all Peptides & GLP-1 education
An independent editorial review with no affiliate links and no compensation. PlexusDx has no commercial relationship with Ivim Health or its parent company.
"Peptides" is a broad label, and in the weight-management context it usually points to a specific, well-studied class: GLP-1 receptor agonists and dual agonists. Understanding that category clarifies what a program like Ivim Health actually offers. This editorial review, current as of April 2026, frames the peptide landscape, the model itself, and the genetic layer it leaves untouched. It is educational and not a buying recommendation.
The peptide and GLP-1 category, briefly
Peptides are short chains of amino acids that signal within the body. In weight management, the relevant peptides are GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, and the GIP and GLP-1 dual agonist tirzepatide. A telehealth service like Ivim Health prescribes within this class rather than inventing new compounds, and its current offering is described on Ivim Health's official website.
Which peptide classes telehealth programs use
Most programs in this space concentrate on the compounds with robust weight-management evidence. The STEP program studied semaglutide, published in The New England Journal of Medicine in 2021; the SURMOUNT program studied tirzepatide in 2022; and SURMOUNT-OSA examined tirzepatide for obstructive sleep apnea in 2024. Trial populations and endpoints differ, and individual outcomes vary from the reported averages.
How Ivim Health fits the peptide landscape
Structurally, Ivim Health operates like other telehealth-plus-compounding programs: intake, licensed clinician review, a prescription routed to a retail or 503A compounding pharmacy, and ongoing follow-up. What varies across programs is the provider type, the pharmacy partner, and the subscription model. The peptide itself is drawn from the same well-studied class regardless of which service prescribes it.
Peptides act on pathways your genes shape
Every peptide in this class works on biology your genes already influence. The GLP1R gene encodes the receptor these compounds target, FTO shapes fat-mass regulation, and MC4R governs satiety signaling. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights to map that baseline. It does not predict response to any specific peptide or medication.
Peptides that belong in a different conversation
Not every peptide discussed online is appropriate for a weight-management program. Some compounds remain investigational, are not FDA-approved, and lack the trial base of the GLP-1 class; they are not part of PlexusDx's weight-management offering and warrant caution. The peptides worth focusing on here are the well-studied GLP-1 and dual-agonist compounds with published outcomes, which is why this review keeps the emphasis squarely on that evidence-backed class.
PlexusDx offers the most-studied weight-management peptides through its Weight Management Protocols as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral, paired with genetic context.
Not affiliated: PlexusDx has no commercial relationship with Ivim Health and does not endorse the companies named in this review.
Related reading on PlexusDx: GLP 1 Hormone, What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist.
This educational review compares approaches in the GLP-1 and peptide telehealth space. PlexusDx is not affiliated with Ivim Health. The Precision Peptide Genetic Test analyzes how genes influence peptide-related pathways and does not predict any specific medication's effect. Consult a qualified healthcare provider before starting a protocol.
To ground a peptide decision in your own data, take the Precision Peptide Genetic Test first, then explore the Weight Management Protocols.
Frequently Asked Questions
What peptides does a program like Ivim Health use?
Weight-management telehealth programs generally prescribe GLP-1 receptor agonists such as semaglutide and the GIP and GLP-1 dual agonist tirzepatide, the compounds with the strongest weight-management evidence. Ivim Health prescribes within this class rather than offering novel peptides. Confirm its current offering on the brand's own website.
Are these peptides FDA-approved?
The branded forms of these compounds are FDA-approved for specific uses, while compounded versions prepared by 503A pharmacies are not FDA-approved. Which you receive depends on the program and dispensing route. Investigational compounds are a separate matter and are not part of PlexusDx's weight-management offering.
How do my genes relate to peptide therapy?
Peptides act on pathways your genes already shape. Variants in GLP1R, FTO, and MC4R describe your baseline receptor and appetite biology. The Precision Peptide Genetic Test maps that context but does not predict how any specific peptide will perform for you. It informs a conversation with your provider rather than forecasting an outcome.
Does PlexusDx sell every peptide people ask about?
No. PlexusDx focuses on the well-studied GLP-1 and dual-agonist compounds through its Weight Management Protocols and does not offer investigational peptides. If you encounter marketing for unapproved or investigational compounds, treat it cautiously and discuss any peptide interest with a qualified healthcare provider before acting. Evidence and approval status should guide the conversation, not hype.
This article is part of the PlexusDx Education Hub. Continue with more Peptides and GLP-1 education. Browse all Peptides & GLP-1 education
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Henry Meds vs Ivim Health: How Each Dispenses GLP-1 Meds
Is Ivim Health Legit? Licensure and the 503A Pathway